L Arnould

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. ncbi request reprint [Sclerosing epithelioid fibrosarcoma: a fibrosarcoma with a very long course]
    L Arnould
    Service d Anatomie et Cytologie Pathologiques, Centre G F Leclerc, Dijon, France
    Ann Pathol 20:154-7. 2000
  2. pmc SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases
    Jocelyne Jacquemier
    Institut Paoli Calmettes, Biopathology Department, 232 Bd Ste Marguerite, 13009, Marseille, France
    BMC Cancer 13:351. 2013
  3. doi request reprint Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH)
    Laurent Arnould
    Biology and Tumor Pathology Department, Centre Georges Francois Leclerc, Dijon, France
    Mod Pathol 25:675-82. 2012
  4. ncbi request reprint Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification
    Laurent Arnould
    CLCC G F Leclerc and 1FR100, Dijon, France
    Clin Cancer Res 13:6404-9. 2007
  5. pmc Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
    L Arnould
    Department of Pathology, Centre G F Leclerc, Dijon 21000, France
    Br J Cancer 94:259-67. 2006
  6. pmc Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer
    L Arnould
    Department of Pathology, Centre GF Leclerc, 1 rue Pr Marion, 21034 Dijon Cedex, France
    Br J Cancer 88:1587-91. 2003
  7. ncbi request reprint [Management of ductal carcinoma in situ by the pathologist: current questions]
    Laurent Arnould
    Service de Pathologie, Centre Georges Francois Leclerc, 1 rue Professeur Marion, BP 77980, 21079 Dijon Cedex
    Ann Pathol 23:534-46. 2003
  8. ncbi request reprint [Basic anatomopathological features of tumors and their extensions. Prognostic and therapeutic implications]
    L Arnould
    Service d Anatomie et de Cytologie Pathologiques, Centre G F Leclerc, 1, rue Professeur Marion, BP 7798, 21080 Dijon, France
    Cancer Radiother 6:61s-69s. 2002
  9. ncbi request reprint [Gross tumor volume and clinical target volume in radiotherapy: generalities. Definitions and generalities in anatomic pathology]
    L Arnould
    Service d Anatomie et de Cytologie Pathologiques, Centre Georges Francois Leclerc, 1, rue Professeur Marion, BP 7798, 21080 Dijon, France
    Cancer Radiother 5:488-95. 2001
  10. doi request reprint Neoadjuvant therapy for breast cancer has no benefits on overall survival or on the mastectomy rate in routine clinical practice. A population-based study with a median follow-up of 11 years using propensity score matching
    I Le Ray
    Biostatistics and Epidemiology Unit, EA 4184, Centre Georges Francois Leclerc CGFL, Dijon, France
    Eur J Cancer 48:2300-10. 2012

Detail Information

Publications50

  1. ncbi request reprint [Sclerosing epithelioid fibrosarcoma: a fibrosarcoma with a very long course]
    L Arnould
    Service d Anatomie et Cytologie Pathologiques, Centre G F Leclerc, Dijon, France
    Ann Pathol 20:154-7. 2000
    ....
  2. pmc SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases
    Jocelyne Jacquemier
    Institut Paoli Calmettes, Biopathology Department, 232 Bd Ste Marguerite, 13009, Marseille, France
    BMC Cancer 13:351. 2013
    ....
  3. doi request reprint Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH)
    Laurent Arnould
    Biology and Tumor Pathology Department, Centre Georges Francois Leclerc, Dijon, France
    Mod Pathol 25:675-82. 2012
    ..They could also be used for quality controls and immunohistochemistry calibration...
  4. ncbi request reprint Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification
    Laurent Arnould
    CLCC G F Leclerc and 1FR100, Dijon, France
    Clin Cancer Res 13:6404-9. 2007
    ..Using FISH and IHC, we analyzed the relationship between pathologic complete response to trastuzumab-based neoadjuvant therapy and level of HER-2 amplification in locally advanced breast cancer...
  5. pmc Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
    L Arnould
    Department of Pathology, Centre G F Leclerc, Dijon 21000, France
    Br J Cancer 94:259-67. 2006
    ..These results suggest that trastuzumab plus taxanes lead to enhanced NK cell activity, which may partially account for the synergistic activity of trastuzumab and docetaxel in breast cancer...
  6. pmc Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer
    L Arnould
    Department of Pathology, Centre GF Leclerc, 1 rue Pr Marion, 21034 Dijon Cedex, France
    Br J Cancer 88:1587-91. 2003
    ..Our results allow us to think that, in many laboratories, CISH may also be an excellent method to calibrate the IHC procedures or, as a quality control test, to check regularly that the IHC signal is in agreement with the gene status...
  7. ncbi request reprint [Management of ductal carcinoma in situ by the pathologist: current questions]
    Laurent Arnould
    Service de Pathologie, Centre Georges Francois Leclerc, 1 rue Professeur Marion, BP 77980, 21079 Dijon Cedex
    Ann Pathol 23:534-46. 2003
    ..Indeed, if dealt with adequately, such lesions should almost never affect the patient's long-term survival...
  8. ncbi request reprint [Basic anatomopathological features of tumors and their extensions. Prognostic and therapeutic implications]
    L Arnould
    Service d Anatomie et de Cytologie Pathologiques, Centre G F Leclerc, 1, rue Professeur Marion, BP 7798, 21080 Dijon, France
    Cancer Radiother 6:61s-69s. 2002
    ..Sometimes, the description of modifications induced by neoadjuvant therapy, as chemo or radiotherapy, allows the evaluation of the efficiency of these treatments...
  9. ncbi request reprint [Gross tumor volume and clinical target volume in radiotherapy: generalities. Definitions and generalities in anatomic pathology]
    L Arnould
    Service d Anatomie et de Cytologie Pathologiques, Centre Georges Francois Leclerc, 1, rue Professeur Marion, BP 7798, 21080 Dijon, France
    Cancer Radiother 5:488-95. 2001
    ..Finally, in certain cases, the description of modifications induced by neoadjuvant therapy allows the evaluation of the treatment's efficacy...
  10. doi request reprint Neoadjuvant therapy for breast cancer has no benefits on overall survival or on the mastectomy rate in routine clinical practice. A population-based study with a median follow-up of 11 years using propensity score matching
    I Le Ray
    Biostatistics and Epidemiology Unit, EA 4184, Centre Georges Francois Leclerc CGFL, Dijon, France
    Eur J Cancer 48:2300-10. 2012
    ..Our objective was to assess the impact of neoadjuvant chemotherapy on OS and on the rate of mastectomy in patients with non-metastatic primary operable breast carcinoma in routine practice...
  11. ncbi request reprint Malignant extraovarian endometriosis: a review
    L Benoit
    Service de Chirurgie Digestive, Thoracique, et Cancérologique, CHU du Bocage, 2, Bd du Maréchal de Lattre de Tassigny, BP 77908, 21079 Dijon Cedex, France
    Eur J Surg Oncol 32:6-11. 2006
    ..Malignant transformation in extra-ovarian endometriosis is a rare but known complication. This distinct pathological entity is reviewed with a specific focus on aetiology and treatment...
  12. doi request reprint Impact of neoadjuvant chemotherapy on survival in breast cancer patients in daily practice: a population-based study
    T S Dabakuyo
    Breast and Gynecologic Cancer Registry of Côte d Or, Centre Georges Francois Leclerc, Dijon, EA 4184, France
    Eur J Cancer Care (Engl) 22:638-47. 2013
    ..Among these patients, 92 (37%) were matched. In this population, multivariate analyses showed that the use of NC did not independently influence RS: relative excess risk = 0.93 (0.50, 1.71). ..
  13. pmc Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma
    F Vegran
    Centre Georges Francois Leclerc, IFR Santé STIC, Dijon Cedex, France
    Br J Cancer 101:1357-64. 2009
    ..We examined the ability of microarray analyses to determine the potential markers of pathological complete response (pCR)...
  14. ncbi request reprint The role of surgery and treatment trends in uterine sarcoma
    L Benoit
    Service de Chirurgie Digestive, Thoracique et Cancérologique, Hopital du Bocage, CHU, Dijon, France
    Eur J Surg Oncol 31:434-42. 2005
    ..To report a series of uterine sarcomas treated in one institution...
  15. doi request reprint Impact of immunohistochemical markers, CK5/6 and E-cadherin on diagnostic agreement in non-invasive proliferative breast lesions
    G MacGrogan
    Department of Pathology, Institut Bergonie, Bordeaux, France
    Histopathology 52:689-97. 2008
    ..To assess the impact of cytokeratin (CK) 5/6 and E-cadherin immunohistochemistry on diagnostic agreement of non-invasive proliferative breast lesions...
  16. doi request reprint [Management of metastatic HER2-positive breast cancer: present and future]
    S Guiu
    Departement d Oncologie Medicale, centre de lutte contre le cancer Georges François Leclerc, 1, rue Professeur Marion, 21000 Dijon, France
    Bull Cancer 97:365-83. 2010
    ..Data regarding cardiotoxicity and the use of trastuzumab under particular clinical circumstances (brain metastases, pregnancy) are also reviewed...
  17. ncbi request reprint Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial
    B P Coudert
    Oncology, Surgery, Radiology CAC GF Leclerc, Dijon, France
    Ann Oncol 17:409-14. 2006
    ..Trastuzumab-based pre-operative systemic (neo-adjuvant) therapy (PST) also appears promising, warranting further investigation...
  18. pmc T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival
    S Ladoire
    Department of Medical Oncology, Georges François Leclerc Center, Centre de Recherche Inserm 866, Faculte de Medecine, 7 Boulevard Jeanne d Arc, Dijon 21000, France
    Br J Cancer 105:366-71. 2011
    ..We hypothesised that the presence of such T cells in the tumour immune infiltrates following neoadjuvant chemotherapy would predict patient survival...
  19. ncbi request reprint [Malignant tumours arising in extraovarian endometriosis: three case reports and review of the literature]
    L Benoit
    Service de Chirurgie, Centre G F Leclerc, 1 rue du Pr Marion, BP 77980, 21079 Dijon Cedex, France
    Ann Chir 129:376-80. 2004
    ..The incidence of carcinoma arising in endometriosis is about 0.8% and 5-year survival rate of pelvic endometrioid form is about a 100% after surgery and radiotherapy...
  20. ncbi request reprint [Conservative surgery in breast cancer: combination skin incision for a better cosmetic result]
    L Benoit
    Service de Chirurgie, Centre G F Leclerc, 1, rue du Professeur Marion, BP 77980, 21079 Dijon Cedex, France
    Ann Chir 129:310-2. 2004
    ..The skin incision have an "amphore-like" appearance. It allows an easy mammoplasty with all cancerologic securities...
  21. ncbi request reprint Concurrent lymphoma and metastatic breast carcinoma in the axillary, confounding sentinel lymph-node biopsy
    L Benoit
    Service de Chirurgie, Centre G F Leclerc, 1 rue du Pr Marion, B P 77980, Dijon Cedex 21079, France
    Eur J Surg Oncol 30:462-3. 2004
    ..Tumor collision lead to a mistake in the appropriate staging of the breast tumor by sentinel lymph-node biopsy. We believe that sentinel lymph-node biopsy should be avoided in cases of lymphoma...
  22. ncbi request reprint [Histological and cytopathological cancer specimens: good practice in operating room]
    L Benoit
    Service de Chirurgie, Centre G F Leclerc, 1, rue du Professeur Marion, BP 77980, 21079 Dijon Cedex, France
    Ann Chir 128:637-41. 2003
    ....
  23. ncbi request reprint [Ductal in situ carcinoma: is it ethical to consider the breast conserving therapy as a standard?]
    I Barillot
    Departement de Radiotherapie, centre de lutte contre le cancer Georges François Leclerc, 1, rue du Professeur Marion, 21079 Dijon, France
    Cancer Radiother 8:9-20. 2004
    ..This review presents the arguments that permit to justify the reasoned choice of the different therapeutic options according to the clinico-pathological situations...
  24. ncbi request reprint [Metastatic renal cell carcinoma to the thyroid gland: report of seven cases and review of the literature]
    L Benoit
    Service de Chirurgie, Centre G F Leclerc, 1, rue du Professeur Marion, BP 77980, 21079 Dijon, France
    Ann Chir 129:218-23. 2004
    ..The aim of this study was to retrospectively report clinical manifestations, type of treatment, survival rate of thyroid metastases from renal carcinoma...
  25. ncbi request reprint [Evolution of therapeutic practices and survival of ovarian cancer in Bourgandi between 1982-1996: a registry-based study]
    L Benoit
    Service de Chirurgie, Centre G F Leclerc, 1, rue du Professeur Marion, BP 77980, 21079 Dijon Cedex, France
    Ann Chir 129:415-21. 2004
    ..All the patients were registered in the "Registre des Cancers Gynécologiques de Côte-d'Or-France"...
  26. ncbi request reprint [Intrathoracic localisation of desmoid tumours: a familial case of isolated desmoid tumours and current published data]
    L Benoit
    Service de Chirurgie Digestive, Thoracique et Cancérologique, CHU du Bocage, 2, boulevard Mal de Lattre de Tassigny, 21079 Dijon Cedex, France
    Ann Chir 131:459-63. 2006
    ..One year later, the desmoid tumor had completely disappeared. Even though wide surgical excision is an essential element in the treatment of desmoid tumors, spontaneous regression may occur in very advanced disease...
  27. ncbi request reprint [Standards, options and recommendations for the composition of anatomic and surgical pathology reports or cytopathology reports in oncology]
    L Arnould
    Centre Georges Francois Leclerc, Dijon
    Ann Pathol 23:79-95. 2003
    ..The methodology is based on literature review and critical appraisal by a multidisciplinary group of experts, with feedback from specialists in cancer care delivery...
  28. pmc Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes
    S Audia
    INSERM, UMR 866, Faculty of Medicine and Pharmacy, Hospital du Bocage, Dijon, France
    Clin Exp Immunol 150:523-30. 2007
    ..Moreover, cyclophosphamide administration may not represent an optimal therapy to eliminate Treg, which further underlines the need to identify specific agents that would selectively deplete these cells...
  29. ncbi request reprint [HER2 gene amplification assay: is CISH an alternative to FISH?]
    Yves Denoux
    Service d Anatomie Pathologique, Centre Francois Baclesse, 14076 Caen Cedex 5
    Ann Pathol 23:617-22. 2003
    ..We present details of this technique, which may be more familiar for the pathologists than FISH, because reading analysis is similar to that of immunohistochemical staining...
  30. ncbi request reprint [Brenner tumour of the vagina]
    Marion Gelly-Marty
    Département d Anatomie et Cytologie Pathologiques, Centre G F Leclerc, 1 rue du Professeur Marion, 21079 Dijon Cedex
    Ann Pathol 27:310-2. 2007
    ..Only five cases have been reported in the vagina. We report a sixth case and discuss the histogenesis of this tumour, as well as the differential diagnosis with the mixed tumour of the vagina...
  31. ncbi request reprint Progesterone enhances cytokine-stimulated nitric oxide synthase II expression and cell death in human breast cancer cells
    Fatima Bentrari
    EPHE INSERM 517, Faculty of Medicine, University of Bourgogne, Dijon, France
    Lab Invest 85:624-32. 2005
    ..Our findings help clarify the role of steroid hormones in NOSII expression as well as the effect on cell viability and may suggest novel approaches towards hormonotherapy and the treatment of cancer...
  32. pmc Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray
    Frederic Bibeau
    Department of Pathology, Centre Regional de Lutte contre le Cancer Val d Aurelle, 34298, Montpellier, Cedex 5, France
    Virchows Arch 449:281-7. 2006
    ..In conclusion, EGFR expression measured in tissue sections from primary CRC and their related metastases was found to be similar and frequent, but it was significantly underestimated by the TMA technique...
  33. ncbi request reprint Re: HER2 testing in the real world
    Anne Vincent-Salomon
    J Natl Cancer Inst 95:628; author reply 628-9. 2003
  34. ncbi request reprint Breast carcinoma metastasis within granulosa cell tumor of the ovary: morphologic, immunohistologic, and molecular analyses of the two different tumor cell populations
    Laurent Arnould
    Department of Pathology, Centre GF Leclerc, and INSERM, U 517, Faculte de Medecine, Dijon, France
    Hum Pathol 33:445-8. 2002
    ..In contrast, granulosa cell tumor areas did not show any loss of heterozygosity or instability for the microsatellites analyzed...
  35. ncbi request reprint Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial
    Bruno P Coudert
    Department of Oncology, CAC G F Leclerc and IFR 100, Dijon, France
    J Clin Oncol 25:2678-84. 2007
    ..Trastuzumab-based preoperative systemic therapy (PST; neoadjuvant therapy) also appears promising, warranting further investigation...
  36. ncbi request reprint Patterns of loss of heterozygosity in breast carcinoma during neoadjuvant chemotherapy
    Claire Oudin
    Laboratory of Molecular Genetics, Centre Georges Francois Leclerc, Inserm U 517, Dijon, France
    Int J Oncol 30:1145-51. 2007
    ....
  37. ncbi request reprint [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy
    Alina Berriolo-Riedinger
    Department of Nuclear Medicine, Centre Georges Francois Leclerc, Dijon, France
    Eur J Nucl Med Mol Imaging 34:1915-24. 2007
    ..To evaluate, in breast cancer patients treated by neoadjuvant chemotherapy, the predictive value of reduction in FDG uptake with regard to complete pathological response (pCR)...
  38. ncbi request reprint Clinical value of mitochondrial mutations in colorectal cancer
    Astrid Lievre
    INSERM U490 Laboratoire de Toxicologie Moléculaire, 45 Rue des Saints Peres, 75006 Paris, France
    J Clin Oncol 23:3517-25. 2005
    ....
  39. ncbi request reprint Is there an immunohistochemical technique definitively valid in epidermal growth factor receptor assessment?
    Frederique Penault-Llorca
    Centre Jean Perrin, Departement de Pathologie, 63011 Clermont Ferrand Cedex, France
    Oncol Rep 16:1173-9. 2006
    ..No scoring system showed, to date, its accuracy, and more studies have to be conducted with an evaluation of the response to cetuximab, possibly with a correlation with FISH amplification in colorectal carcinoma...
  40. ncbi request reprint Comparative analysis of molecular alterations in fibroadenomas associated or not with breast cancer
    Noreli Franco
    Laboratory of Molecular Genetics, Centre Georges Francois Leclerc, Dijon, France
    Arch Surg 138:291-5. 2003
    ..In this study we asked whether molecular changes could discriminate fibroadenoma, which is one of the most common benign breast disease lesions associated or not with breast cancer...
  41. ncbi request reprint [Standards, Options and Recommendations for the management of ductal carcinoma in situ of the breast (DCIS): update 2004]
    Bruno Cutuli
    Oncologue radiothérapeute, Polyclinique de Courlancy, Reims
    Bull Cancer 92:155-68. 2005
    ..Results : Clinical guidelines have been defined for the management of diagnosis, treatment, follow-up, and treatment of recurrence of DCIS. The issue of hormone replacement therapy has also been addressed in the context of DCIS...
  42. ncbi request reprint [To stimulate or to inhibit nitric oxide production in mammary tumors?]
    Nolwenn Gauthier
    EPHE Inserm, Laboratoire d immunologie et immunothérapie des cancers, unité 517 mort cellulaire et cancer, IFR 100 et Université de Bourgogne, 7 Boulevard Jeanne d Arc, 21079 Dijon
    Bull Cancer 91:705-12. 2004
    ..However, researches aimed at managing tumor cells to produce NO sufficient to induce their death may be fruitful since, be tumor targeting successful, no general toxicity would be encountered...
  43. ncbi request reprint [Mural nodules of anaplastic carcinoma in bilateral ovarian borderline mucinous cystadenoma: a case report]
    Celine Guilbeau
    Service d Anatomie et Cytologie Pathologiques, Centre G F Leclerc, 1 rue Pr Marion, BP 77980, 21079 Dijon Cedex
    Ann Pathol 23:340-4. 2003
    ..This tumor was synchronous with a renal cell carcinoma. We give details about the classification, the differential diagnoses and prognosis of these nodules...
  44. ncbi request reprint [EGFR expression in colorectal cancer and role in tumorigenesis]
    Frederique Penault-Llorca
    Centre Jean Perrin, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex
    Bull Cancer 92:S5-11. 2005
    ..EGFR testing may be required before targeted treatment. An exciting endpoint might be the functional and dynamic evaluation of EGFR and downstream proteins for patients, before and during treatment...
  45. doi request reprint Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells
    Sylvain Ladoire
    Centre Regional de Lutte Contre le Cancer, Dijon, France
    Clin Cancer Res 14:2413-20. 2008
    ..To assess the capacity of neoadjuvant chemotherapy to affect T-cell infiltration in breast cancer, we evaluated CD3 and CD8 infiltrates, and the Foxp3 immunosuppressive T cells...
  46. ncbi request reprint [Architectural disorganization and large cells]
    Marie Paule Algros
    Service d Anatomie et Cytologie Pathologiques, CHU Jean Minjoz, Boulevard Fleming, 25030 Besancon
    Ann Pathol 23:67-8. 2003
  47. ncbi request reprint Preventing lymphedema and morbidity with an omentum flap after ilioinguinal lymph node dissection
    Laurent Benoit
    Service de Chirurgie Digestive, Thoracique, et Cancérologique, CHU du Bocage, B P 77908, 21079, Dijon Cedex, France
    Ann Surg Oncol 12:793-9. 2005
    ....
  48. ncbi request reprint High inter-observer agreement in immunohistochemical evaluation of HER-2/neu expression in breast cancer: a multicentre GEFPICS study
    Magali Lacroix-Triki
    Department of Pathology, Institut Claudius Regaud, 20 24 rue du Pont saint Pierre, 31052 Toulouse Cedex, France
    Eur J Cancer 42:2946-53. 2006
    ..82). As expected, the score 2+ group showed poor agreement (kappa=0.38). A quality assurance process showed that ring studies and adherence to national guidelines greatly improve inter-observer reproducibility...
  49. ncbi request reprint Low urine osmolarity as a determinant of cisplatin-induced nephrotoxicity
    Emmanuel Polycarpe
    INSERM 517, Faculty of Medicine, Dijon, France
    Int J Cancer 111:131-7. 2004
    ..Our results show that low urine osmolarity could be a major determinant in the increase of cisplatin-induced nephrotoxicity and justify the widely used concurrent infusion of osmotically active substances during intravenous hydration...
  50. ncbi request reprint Chronic high-fat diet affects intestinal fat absorption and postprandial triglyceride levels in the mouse
    Valerie Petit
    Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l Alimentation, 5170 Centre National de la Recherche Scientifique 1214 Institut National de la Recherche Agronomique Université de Bourgogne, Dijon, France
    J Lipid Res 48:278-87. 2007
    ..These data demonstrate that a chronic high-fat diet greatly affects intestinal physiology and body lipid use in the mouse...